Philips announced that its LumiGuide 3‑D Device Guidance system will be commercially available for order in Europe and the United States beginning in January 2026. The announcement was made at the Radiological Society of North America (RSNA) 2025 conference on December 1 2025, marking the first time the company will offer the technology to a broad customer base.
LumiGuide is the first real‑time, AI‑enabled, light‑based 3‑D navigation solution for image‑guided therapy. It uses Fiber‑Optic RealShape (FORS) technology to render full‑color, high‑resolution images from any angle, and it integrates seamlessly with Philips’ Azurion platform. Clinical data from a limited release in late 2023 show that the system has already been used in more than 2,000 procedures, with 900 patients treated across nine aortic centers and the 1,000th patient treated in September 2024. The technology can reduce procedure time by up to 37 % and lower dose‑area product (DAP) by up to 56 %, directly addressing radiation safety and procedural efficiency concerns in vascular and other interventional procedures.
The launch expands Philips’ presence in the image‑guided therapy market, a segment that is growing as hospitals seek lower‑risk, faster‑procedural solutions. By offering a radiation‑free navigation alternative, Philips differentiates itself from competitors that rely on traditional X‑ray guidance, potentially capturing new customers and increasing market share in a high‑margin therapeutic segment. The product’s integration with the Azurion platform leverages Philips’ existing customer base, simplifying adoption for hospitals already using the platform and reinforcing Philips’ strategy to embed AI across its health‑tech portfolio.
Stacey Beske, Philips’ Business Leader for Image‑Guided Therapy Devices, said the expansion “moves LumiGuide from a limited to full commercial availability, a milestone that expands access to advanced image‑guided therapy.” Chief Medical Officer Atul Gupta added that the system “helps clinicians treat complex vascular disease with precision and safety, while reducing radiation risk for patients and teams.” A practicing vascular surgeon, Dr. Adam Beck, noted that the system “improves efficiency, reduces procedure time, and brings fluoroscopy time near zero.”
The announcement comes on the heels of Philips’ Q3 2025 earnings, which showed a 3 % increase in comparable sales and an adjusted EBITA margin of 12.3 %. The company’s strong financial performance underscores its capacity to invest in innovative solutions like LumiGuide while maintaining profitability. The product launch is expected to contribute to future revenue growth by tapping into a growing market for radiation‑free interventional technologies and reinforcing Philips’ leadership in AI‑driven medical devices.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.